Status:
UNKNOWN
Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection
Lead Sponsor:
Hanyang University
Conditions:
Latent Tuberculosis Infection
Eligibility:
All Genders
19+ years
Brief Summary
The investigators aim to study the prevalence of adverse reactions of anti-tuberculosis (TB) drugs in latent tuberculosis infection (LTBI), and determine the risk factors of anti-TB drug-related toxic...
Detailed Description
Further study details as provided by Hanyang University Hospital This study is prospective study of newly diagnosed LTBI in HCWs at Hanyang University Hospital, a tertiary referral hospital in South ...
Eligibility Criteria
Inclusion
- 19 years or more
- Identified latent tuberculosis infection (LTBI) in Korean health care workers, using whole-blood interferon-r release assays
Exclusion
- Subjects who do not want to participate the present study
- Subjects who do not receive LTBI treatment due to abnormal liver function test (i.e, liver cirrhosis etc)
- Subjects with history of previously treated TB
- Subjects with active tuberculosis infection
Key Trial Info
Start Date :
June 19 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2018
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03312647
Start Date
June 19 2017
End Date
May 1 2018
Last Update
October 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sang-Heon Kim
Seoul, South Korea